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Personalized screening intervals for
measurement of N-terminal pro-B-type
natriuretic peptide improve efficiency of
prognostication in patients with chronic
heart failure
Anne-Sophie Schuurman1,2, Anirudh Tomer3,
K Martijn Akkerhuis1,2, Jasper J Brugts1,
Alina A Constantinescu1, Jan van Ramshorst4,
Victor A Umans4, Eric Boersma1,2, Dimitris Rizopoulos3 and
Isabella Kardys1,2
Although natriuretic peptide levels have been associat-
ed with incident heart failure and prognosis of heart
failure patients,1,2 trials on natriuretic peptide-guided
treatment have provided inconsistent results.3 Existing
trials mostly used predefined screening intervals and
target levels, which do not account for variations in
temporal patterns of circulating biomarkers between
individuals. This may hamper their potential use for
therapy guidance. In contrast, a personalized screening
approach with screening intervals and target levels
based on the evolution of biomarkers in individual
patients may further improve risk assessment and ther-
apy guidance. Such personalized screening intervals
maximize information gain on the individual patients’
disease progression, while minimizing the necessary
number of measurements.4
In the Bio-SHiFT study, we demonstrated that indi-
vidual temporal patterns of serially measured chronic
heart failure (CHF)-related biomarkers are associated
with the prognosis of CHF patients.5 We also demon-
strated a method to obtain a patient-specific dynamic
estimate of prognosis. This estimate is updated after
every additional measurement, as each measurement
provides additional information.5 This personalized
risk assessment can also be used to derive personalized
screening intervals for future CHF patients. However,
the benefits of this approach, over predefined screening
intervals and targets, have not yet been investigated
in CHF patients. Here, we compare personalized
scheduling of N-terminal pro-B-type natriuretic
peptide (NT-proBNP) measurements to a predefined,
fixed scheduling approach.
In 263 stable CHF patients from the Bio-SHiFT
study, NT-proBNP was measured trimonthly accord-
ing to a prespecified, fixed schedule.5 The composite
primary endpoint (PE) consisted of cardiac death,
cardiac transplantation, left ventricular assist device
implantation or heart failure hospitalization. Using
joint models for time-to-event and longitudinal data,
we modelled the association between repeated NT-
proBNP measurements and the PE.5 Subsequently,
we performed a simulation study where we generated
750 patients with baseline characteristics and NT-
proBNP profiles similar to the 263 patients included
in the Bio-SHiFT study. We divided these patients
into a training (700 patients) and testing (50 patients)
set.4 In the training set, we fitted a new joint model for
NT-proBNP. We compared scheduling of NT-proBNP
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Figure 1. (a) Use the joint model to find the time point at which the patients’ cumulative risk of PE is 7.5%. The next measurement
will be scheduled between the current visit and this time point. (b) Schedule the next measurement within this time window at the
optimal time point at which we expect the maximum information gain on the patient’s prognosis (c) Perform the next measurement
and update the personalized cumulative risk of PE. Subsequently, again, find the time point at which the patients’ cumulative risk is
7.5%. (d) Definition of high-risk interval as used in the personalized scheduling approach. The ‘true event time’ is generated by the
simulation study. Based on the estimated NT-proBNP profile, the patient’s 3-month risk of PE (%) is estimated by the personalized
scheduling approach (curve). The time point at which this 3-month risk of PE exceeds the risk threshold is defined as the ‘estimated
intervention time’. The start of the high-risk interval is defined as the estimated intervention time minus the true event time (in
months). (e) Comparison of personalized and fixed scheduling using a risk threshold of 7.5% over a 3-month period.
Left: Number of measurements. Right: Start of high-risk intervals (in months), with the true event time being time zero.
NT-proBNP: N-terminal pro b-type natriuretic peptide; PE: primary endpoint.
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measurements according to a fixed screening design
and a personalized screening design in the testing set
of patients, using the joint model developed based on
the training set. Specifically, in the personalized screen-
ing design, we derived a personalized risk profile using
the previously measured NT-proBNP levels as well as
the current NT-proBNP level (Figure 1a). Then the
fitted joint model was used to find the time point at
which the patients’ cumulative risk of PE was 7.5%.
The next NT-proBNP measurement was scheduled
between the current outpatient visit and this time
point (Figure 1b). Subsequently, we used the fitted
joint model to estimate the expected information gain
on the patient’s prognosis at every time point within
this specified time window.4 Then, based on the
Kullback-Leibler divergence, we scheduled the next
NT-proBNP measurement at the optimal time point
at which we expected the maximum information gain
on the patient’s prognosis (Figure 1c). After this addi-
tional NT-proBNP measurement was performed in the
patient, the personalized cumulative risk of PE was
updated. Based on this updated personalized cumula-
tive risk of PE, again the time point at which the cumu-
lative risk of PE is 7.5% was determined. If the
personalized cumulative risk of PE within 3 months
was less than 7.5%, we proceeded to schedule the
next NT-proBNP measurement. However, if the per-
sonalized cumulative risk of PE within the next 3
months exceeded 7.5%, scheduling was stopped in
order to adjust therapy and avoid the imminent PE.4
We compared personalized scheduling with fixed tri-
monthly scheduling in terms of the capability to iden-
tify the start of high-risk intervals (i.e. whether timely
intervention was possible before occurrence of PE) and
number of measurements needed (Figure 1(d)). Apart
from using the risk threshold of 7.5% over a three-
month period, we repeated the analysis using 5% and
10% risk thresholds.
The mean age of the 263 original Bio-SHiFT
patients was 66.7 (12.6) years and 71.9% were men
(Table 1). The median baseline NT-proBNP value
was 137.3 (interquartile range (IQR): 51.7–272.6)
pmol/L. During a median follow-up of 2.2 (IQR: 1.4–
2.5) years, a median of nine (IQR: 5–10) NT-proBNP
measurements per patient were performed. The PE
occurred in 70 patients (26.6%). After adjustment for
age, gender, diabetes mellitus, New York Heart
Association class, body mass index and renal function,
serially measured NT-proBNP remained independently
associated with the PE (hazard ratio per doubling of
NT-proBNP level: 2.20, 95% confidence interval: 1.84–
2.68). The baseline characteristics of the simulated
patients were similar to those of the Bio-SHiFT study
patients (data not shown). The simulation study
showed that the personalized schedule used fewer
measurements as compared to the fixed schedule
(Figure 1(e)). The personalized schedule used a
median of seven (IQR: 7–8) measurements, while the
fixed used nine (IQR: 8–10). The personalized and fixed
schedules showed similar results regarding the high-risk
interval identified for therapeutic intervention to pre-
vent PE occurrence (the personalized schedule had a
Table 1. Baseline characteristics.
N¼ 263 patients
Demographical characteristics
Age, years 66.7 12.6
Men 189 (71.9)
Caucasian ethnicity 244 (92.8)
Clinical characteristics
Body mass index, kg/m2 27.5 4.7
Heart rate, beat/min 67.2 11.6
Systolic blood pressure, mmHg 121.9 20.4
Diastolic blood pressure, mmHg 72.4 10.9
Features HF
Duration of HF, years 4.6 (1.7–9.9)
NYHA class I or II 194 (73.8)
NYHA class III or IV 69 (26.2)
Left ventricular function
Systolic dysfunction 250 (95.1)
HFPEF 13 (4.9)
LVEF 32.0 11.7
Etiology of HF
Ischemic heart disease 117 (44.5)
Hypertension 34 (12.9)
Cardiomyopathy 68 (25.9)
Unknown 19 (7.2)
Other 25 (9.5)
Medical history
Myocardial infarction 94 (35.7)
PCI 82 (31.2)
CABG 43 (16.3)
Atrial fibrillation 105 (39.9)
Chronic renal failure 136 (51.7)
Diabetes mellitus 81 (30.8)
Hypertension 120 (45.6)
Intoxication
Smoking
Ever 185 (70.3)
Current 26 (9.9)
Medication use
ACE-I or ARB 245 (93.2)
Aldosterone antagonist 179 (68.1)
Diuretic 237 (90.1)
b-blocker 236 (89.7)
Values are mean standard deviation, n (%) or median (interquartile
range).
ACE-I: angiotensin-converting enzyme inhibitors; ARB: angiotensin II
receptor blockers; CABG: coronary artery bypass grafting; HF: heart
failure; HFPEF: heart failure with preserved ejection fraction; IQR:
interquartile range; LVEF: left ventricular ejection fraction; NYHA: New
York Heart Association; PCI: percutaneous coronary intervention.
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median of 6.6 (IQR: 4.5–11.3) months, and the fixed
schedule had a median of 6.3 (IQR: 4.2–10.3); Figure 1
(d), (e)). Therefore, both schedules stopped scheduling
new sampling moments and allowed for timely inter-
vention before the event occurred.
Study limitations that warrant consideration include
the use of only one testing set, and assumptions that
were made when developing the model and defining the
risk thresholds. However, using a risk threshold of 5%
over three months, the fixed and personalized screening
schedules demonstrated similar results for the high-risk
interval. Again, the personalized screening schedule
used fewer measurements as compared to the fixed
screening schedule. Similar results were found for a
risk threshold of 10%.
To conclude, this study demonstrates for the first
time that personalized scheduling of NT-proBNP
measurements in patients with CHF performs similarly
with respect to the prediction of recurrent events, but
requires fewer NT-proBNP measurements than fixed
scheduling. If such personalized scheduling were to be
applied in natriuretic peptide-guided therapy, these
benefits may translate into improved outcomes.
Therefore, a clinical trial incorporating personalized
scheduling warrants consideration.
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